

Pharmacological Targets for Neurorehabilitation

Halina Baran* and Berthold Keplinger

Neurochemical Laboratory, Karl Landsteiner Research Institute for Neurochemistry, Neuropharmacology, Neurorehabilitation and Pain Treatment Mauer, Mauer-Amstetten, Austria

*Corresponding author: Halina Baran, Neurochemical laboratory, Karl Landsteiner Research Institute for Neurochemistry, Neuropharmacology, Neurorehabilitation and Pain Treatment Mauer, 3360 Mauer-Amstetten, Austria, Tel: 43 7475 501 3600; E-mail: Halina.Baran@mauer.lknoe.at

Rec date: Apr 24, 2015; Acc date: Apr 25 2015; Pub date: May 04, 2015

Copyright: © 2015 Baran H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

For almost a quarter of century D-cycloserine, a second line tuberculostatic agent [1], was proposed as a drug to potentiate the glutamatergic receptor function [2] and was introduced to act as a partial agonist at the N-methyl-D-aspartate (NMDA) receptor [2,3].

In respect to the functional activities of D-cycloserine scientists suggested anticonvulsive activities [4,5] and furthermore the application seems to improve memory and cognitive function. Recently we discovered that D-Cycloserine has the ability to block kynurenic acid synthesis [6]. Kynurenic acid, a metabolite along the kynurenine pathway of tryptophan degradation blocks the glycine sites of NMDA glutamatergic receptors [7] and also the nicotine cholinergic receptors [8] and exerts anticonvulsive activities [7].

An animal experimental study gives significant evidence that an increased level of kynurenic acid in the brain enhances memory impairment [9]. On the other hand the plus maze retest paradigm shows an enhancement of memory consolidation after D-cycloserine treatment [10]. This and other significant accumulated experimental findings allowed us to suggest that an increased kynurenic acid level in the CNS of brain disorders might play a role in the impairment of memory and cognition. Subsequently, this consideration challenged neuroscientists and clinicians to find pharmacological and/or therapeutic approaches for better output in neurorehabilitation.

Increased kynurenic acid synthesis in the brain has been found in neuropsychiatric disorders, such as Alzheimer's, Downs Syndrome, [11,12], Schizophrenia [13], HIV encephalopathy [14] and stroke [15-17] or during the aging process [18] and kynurenic acid's involvement in memory and cognition impairment has been suggested.

An improvement of memory in Alzheimer patients has been described after D-cycloserine treatment [19]. Furthermore, in patients with schizophrenia D-cycloserine enhanced learning significantly [20] and D-cycloserine improves memory consolidation and facilitation of behavioural therapy for delusions in patients with schizophrenia [20,21]. Notably, the positive effect of D-cycloserine was enhanced in the presence of neuroleptic drugs [22], confirming that both pharmacological approaches, thus lowering of dopamine neurotransmission by neuroleptic drugs and lowering of kynurenic acid levels due to D-cycloserine treatment are significant therapeutic paradigms in patients with schizophrenia.

D-cycloserine dose-dependently and significantly blocked kynurenine aminotransferase I, II and III (KAT I, II and III) activities in rat liver, and in rat and human brain homogenates [6]. In our further work on the mechanism of D-cycloserine action we demonstrated that lowering of kynurenic acid involves lowering of

pyridoxal-5-phosphat levels [23]. D-cycloserine lowers significantly levels of pyridoxal-5-phosphat which acts as a cofactor in many biochemical reactions involving transamination. Interestingly, Dengler et al. 1962 [24] demonstrated that D-cycloserine inhibits glutamic acid- and dopamine- decarboxylase activities. Dopamine decarboxylase which synthesizes dopamine is - beside kynurenine aminotransferase - a further enzyme which requires pyridoxal-5-phosphat, as well. Therefore it is reasonable to believe that lowering of dopamine and kynurenic acid synthesis due to D-cycloserine action can result in the positive effect of this drug in schizophrenia patients.

It is important to mention one study demonstrating that D-cycloserine did not enhance motor learning or motor skill generalization in neurologically intact adults or in adults after stroke [25], however, authors stated that likely the tasks selected for motor training were not challenging enough. Currently there are several clinical trials ongoing to evaluate the effect of D-cycloserine in different neurological and psychiatric disorders and with different approaches and variable results [26-28].

An improvement of cognition as well as lowering of kynurenic acid synthesis in an in vitro study has been described by using Cerebrolysin [29]. Cerebrolysin is a peptidergic drug, a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, exhibiting neuroprotective and neurotrophic effects in experimental and clinical studies [30-32]. Interestingly, Cerebrolysin is described to be effective in preventing cognitive impairment in different experimental animal models [33-35]. Also human studies indicate that Cerebrolysin improves dementia symptoms and cognitive performance in patients with Alzheimer's disease and in other types of senile dementia [36-38], and also in elderly control subjects [39]. Treatment of stroke patients with Cerebrolysin provided positive effect, too [40].

Although, D-cycloserine and Cerebrolysin lower kynurenic acid content [6, 29] and the effect of both drugs to lower kynurenic acid is additive, at least in an in vitro study (Baran observation), the mechanism of their actions is not elucidated yet.

Tryptophan metabolites are significantly enhanced in the serum and CSF of stroke patients [15-17,41] and increased kynurenic acid levels might have an impact on the impairment of memory and cognition as well as on the development of post-stroke depression which might involve also deficiency of serotonergic activities. Therefore, it is reasonable to believe that lowering of dopamine and also of serotonin synthesis due to D-cycloserine could even promote the progression of depression. And, this could be also one explanation for the lacking positive effect of D-cycloserine treatment in stroke patients.

Movement disturbance up to immobility is a very common condition in stroke patients and might be in part responsible for the increase of kynurenic acid levels in the serum. On the other hand exercise by using stochastic resonance therapy (SRT) and also running activities significantly lowered kynurenic acid levels in the serum of healthy human subjects [42] and of animal experimental model [43]. It is possible that due to forced movement and/or exercise in stroke rehabilitation the kynurenic acid metabolism in the brain could be affected similarly. The importance of exercise for the improvement of chronic stroke patients has been already reported [44].

Rehabilitation of stroke patients by applying repetitive transcranial magnetic stimulation (rTMS) yielded also promising data concerning recovery of sensomotoric and cognitive functions [45,46]. In good correlated with other researches [47-50] and also our study [42] demonstrated the improvement of motor ability in stroke patients after rTMS. Augmentation of motor performance and a moderate reduction of spasticity could be seen [42] and this was in the line with previously published data [51].

We found that the effect of rTMS had a notable impact on the output of occupational therapy if these trials were performed immediately after rTMS. An increase of finger dexterity and amelioration of Barthel Index was observed [42]. Importantly, in patients with high nursing needs less service was required if occupational therapy was performed right way after rTMS [52]. These are important observations for optimizing post stroke rehabilitation.

Furthermore, we could show that rTMS affects L-TRP metabolism in the serum of stroke patients significantly [42]. Among revealed alterations a significant increase of the anthranilic acid/kynurenic acid ratio value due to rTMS was revealed and this change might be important with respect to neuro-modulatory activities and could be involved in the improvement of motor performance too, and this finding need to be further investigated.

The effect of D-cycloserine to act as anticonvulsant has been shown in chemically or electrically induced epileptic models in rats and mice [4,5]. The anticonvulsive activity has been suggested due to action as a partial glycine agonist at the NMDA receptor [3]. A notable enhancement of kynurenic acid levels in the brain regions and in the plasma have been observed in kainic acid induced epilepsy model [53], therefore the mechanism of D-cycloserine to act as an anticonvulsant drug remains questionable.

The mechanism of D-cycloserine action as a partial agonist at the NMDA receptors sites is still unclear. We suggested that lowering of kynurenic acid synthesis due to D-cycloserine is responsible for the drug to act quasi as a partial agonist at the glycine site of the NMDA receptor [6]. Furthermore, since D-cycloserine blocks also decarboxylation of glutamate [24] and experimental study has revealed an enhancement of glutamate levels in the rat brain after D-cycloserine treatment [54], therefore lowering of kynurenic acid and increasing of glutamate levels might result an activation of glutamate receptors. Besides that, diminishing of kynurenic acid synthesis due to D-cycloserine affects cholinergic neurotransmission [8], which has a significant impact on the improvement of memory and/or cognition, too.

References

1. Otten H (1988) Cycloserine (CS) and terizidone (TZ). In: *Antituberculosis Drugs, Handbook of Experimental Pharmacology*. Bartmann K (ed.), Springer-Verlag, Berlin.

2. Kemp JA, Leeson PD (1993) The glycine site of the NMDA receptor--five years on. *Trends Pharmacol Sci* 14: 20-25.
3. Peterson SL (1992) 7-Chlorokynurenic acid antagonizes the anticonvulsant activity of D-cycloserine in maximal electroshock seizures. *Epilepsy Res* 13: 73-81.
4. Baran H, Löscher W, Mevissen M (1994) The glycine/NMDA receptor partial agonist D-cycloserine blocks kainate-induced seizures in rats. Comparison with MK-801 and diazepam. *Brain Res* 652: 195-200.
5. Löscher W, Wlaź P, Rundfeldt C, Baran H, Hönack D (1994) Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats. *Br J Pharmacol* 112: 97-106.
6. Baran H, Kepplinger B (2014) D-Cycloserine lowers kynurenic acid formation--new mechanism of action. *Eur Neuropsychopharmacol* 24: 639-644.
7. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. *Pharmacol Rev* 45: 309-379.
8. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, et al (2001) The brain metabolite kynurenic acid inhibits $\alpha 7$ nicotinic receptor activity and increases non- $\alpha 7$ nicotinic receptor expression: Physiopathological implications. *J Neurosci* 21: 7463-7473.
9. Chess AC, Simoni MK, Alling TE, Bucci DJ (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. *Schizophr Bull* 33: 797-804.
10. Rodgers RJ, Harvest H, Hassall C, Kaddour LA (2011) D-cycloserine enhances memory consolidation in the plus-maze retest paradigm. *Behav Neurosci* 125: 106-116.
11. Baran H, Jellinger K, Deecke L (1999) Kynurenine metabolism in Alzheimer's disease. *J Neural Transm* 106: 165-181.
12. Baran H, Cairns N, Lubec B, Lubec G (1996) Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. *Life Sci* 58: 1891-1899.
13. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, et al. (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. *Neurosci Lett* 313: 96-98.
14. Baran H, Hainfellner JA, Kepplinger B (2012) Kynurenic Acid Metabolism in Various Types of Brain Pathology in HIV-1 Infected Patients. *Int J Tryptophan Res* 5: 49-64.
15. Urbańska EM, Luchowski P, Luchowska E, Pniewski J, Woźniak R, et al. (2006) Serum kynurenic acid positively correlates with cardiovascular disease risk factor, homocysteine: a study in stroke patients. *Pharmacol Rep* 58: 507-511.
16. Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, et al. (2007) Altered kynurenine metabolism correlates with infarct volume in stroke. *Eur J Neurosci* 26: 2211-2221.
17. Kepplinger B, Sedlitzky-Semler B, Eigner S, Kalina P, Berger P, H Baran (2014) Stroke Patients after repetitive Transcranial Magnetic Stimulation (rTMS). Alterations of Tryptophan Metabolites in the Serum. *Int J Neurorehabilitation* 1: 1-11.
18. Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, et al., (2005) Age-related increase of kynurenic acid in human cerebrospinal fluid: Positive correlation with IgG and $\beta 2$ -microglobulin changes. *Neurosignals* 14: 126-135.
19. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI (1996) d-Cycloserine enhances implicit memory in Alzheimer patients. *Neurology* 46: 420-424.
20. Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, et al. (2011) D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. *Schizophr Res* 131: 69-74.
21. Goff DC (2012) D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. *Schizophr Bull* 38: 936-941.
22. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, et al. (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. *Arch Gen Psychiatry* 56: 21-27.

23. Baran H, Kepplinger B (2014) D-cycloserine affects pyridoxal-5-phosphate complex causing a lowering of kynurenic acid formation. *Soc. Neuroscience*, 51:12
24. Dengler HJ, Rauchs E, Rummel W (1962) [On the inhibition of L-glutamic acid and L-DOPA decarboxylase by D-cycloserine and other isoxazolidones]. *Naunyn Schmiedebergs Arch Exp Pathol Pharmacol* 243: 366-381.
25. Cherry KM, Lenze EJ, Lang CE (2014) Combining d-cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke. *J Neurophysiol* 111: 2516-2524.
26. Nadeau SE, Davis SE, Wu SS, Dai Y, Richards LG (2014) A pilot randomized controlled trial of D-cycloserine and distributed practice as adjuvants to constraint-induced movement therapy after stroke. *Neurorehabil Neural Repair* 28: 885-95.
27. Improving stroke rehabilitation: Spacing Effect and D- cyclosetine. (2008-2014) *Clinical Trials*. gov identifier: NCT00720759.
28. Nadeau SE, Davis SE, Wu SS, Dai Y, Richards LG (2014) A pilot randomized controlled trial of D-cycloserine and distributed practice as adjuvants to constraint-induced movement therapy after stroke. *Neurorehabil Neural Repair* 28: 885-95.
29. Baran H, Kepplinger B (2009) Cerebrolysin lowers kynurenic acid formation--an in vitro study. *Eur Neuropsychopharmacol* 19: 161-168.
30. Veinbergs I, Mante M, Mallory M, Masliah E (2000) Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. *J Neural Transm Suppl* 59: 273-280.
31. Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group (2005) Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. *J Neural Transm* 112: 415-428.
32. Riley C, Hutter-Paier B, Windisch M, Doppler E, Moessler H, et al. (2006) A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. *J Neural Transm* 113: 103-110.
33. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W (1999) Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. *Pharmacol Biochem Behav* 62: 239-245.
34. Valousková V, Gschanes A (1999) Effects of NGF, b-FGF, and cerebrolysin on water maze performance and on motor activity of rats: short- and long-term study. *Neurobiol Learn Mem* 71: 132-149.
35. Ren J, Sietsma D, Qiu S, Moessler H, Finklestein SP (2007) Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. *Restor Neurol Neurosci* 25: 25-31.
36. Rütger E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). *Pharmacopsychiatry* 27: 32-40.
37. Ruether E, Husmann R, Kinzler E, Diabl E, Klingler D, et al. (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. *Int Clin Psychopharmacol* 16: 253-263.
38. Crook TH, Ferris SH, Alvarez XA, Laredo M, Moessler H (2005) Effects of N-PEP-12 on memory among older adults. *Int Clin Psychopharmacol* 20: 97-100.
39. Álvarez XA, Lombardi VRM, Corzo L, Pérez P, Pichel V, Laredo M, Hernández A, Freixeiro F, Sampedro C, Lorenzo R, Alcaraz M, Windisch M, Cacabelos R (2000) Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. *J Neural Transm* 59: 315-328.
40. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z (2012) Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. *Stroke* 43: 630-636.
41. Sedlitzky-Semler B, Kepplinger B, Kalina P, Reuss J, Badawi NR, et al., (2014) Alteration of tryptophan metabolites in serum and cerebrospinal fluid in patients after stroke. *Neurologisch MedMedia Verlag Suppl* 2: S 83.
42. Kepplinger B, Baran H, Sedlitzky-Semler B, Badawi NR, Erhart H (2011) Stochastic resonance activity influences tryptophan metabolism in human serum of healthy subjects. *International Journal for Tryptophan Research* 4: 49-60.
43. Kepplinger B, Kalina H, Zeiner D, et al. (2007) Influence of exercise on kynurenic acid levels in the serum. *Amino acids* 33: LVII-LVIII.
44. Kluding PM, Tseng BY, Billinger SA (2011) Exercise and executive function in individuals with chronic stroke: a pilot study. *J Neurol Phys Ther* 35: 11-17.
45. George MS, Wassermann EM, Kimbrell TA, Little JT, Williams WE, et al. (1997) Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. *Am J Psychiatry* 154: 1752-1756.
46. Feinsod M, Kreinin B, Chistyakov A, Klein E (1998) Preliminary evidence for a beneficial effect of low-frequency, repetitive transcranial magnetic stimulation in patients with major depression and schizophrenia. *Depress Anxiety* 7: 65-68.
47. Weiduschat N, Thiel A, Rubi-Fessen I, Hartmann A, Kessler J, et al. (2011) Effects of repetitive transcranial magnetic stimulation in aphasic stroke: a randomized controlled pilot study. *Stroke* 42: 409-415.
48. Corti M, Patten C, Triggs W (2012) Repetitive transcranial magnetic stimulation of motor cortex after stroke: a focused review. *Am J Phys Med Rehabil* 91: 254-270.
49. Hao Z, Wang D, Zeng Y, Liu M (2013) Repetitive transcranial magnetic stimulation for improving function after stroke. *Cochrane Database Syst Rev* 5: CD008862.
50. Pinter MM, Brainin M (2013) Role of repetitive transcranial magnetic stimulation in stroke rehabilitation. *Front Neurol Neurosci* 32: 112-121.
51. Málly J, Dinya E (2008) Recovery of motor disability and spasticity in post-stroke after repetitive transcranial magnetic stimulation (rTMS). *Brain Res Bull* 76: 388-395.
52. Berger P (2011) Auswirkungen der neuronavigierten repetitiven transkranialen Magnetstimulation auf Tätigkeiten des alltäglichen Lebens bei Schlaganfallpatienten. Donau University, Krems, Austria.
53. Baran H, Gramer M, Hönack D, Löscher W (1995) Systemic administration of kainate induces marked increases of endogenous kynurenic acid in various brain regions and plasma of rats. *Eur J Pharmacol* 286: 167-175.
54. Baran H, Gramer M, Löscher W (1995) Alterations in plasma and brain amino acids after administration of the glycine/NMDA receptor partial agonist, D-cycloserine, to mice and rats. *Eur J Pharmacol* 273: 197-201.